CINCINNATI--(BUSINESS WIRE)--Building on its entrance into the mobile healthcare market in 2013, BioRx today announced the introduction of its MyFactor hemophilia app to the Android operating system from Google. The company is also near completion of a corresponding replacement of its iOS app so that it mirrors the Android’s layout and functionality.
Originally launched in October 2013 for Apple iPhones, MyFactor allows hemophilia patients to electronically record bleeding episodes and treatments, and facilitates easy sharing of information with their healthcare team, including physicians, pharmacists, nurses and care coordinators.
“We are very happy to offer the MyFactor app to Android users,” said Eric Hill, co-founder of BioRx. “Over the past year, hundreds of iPhone users have downloaded the app. With our expansion into the larger Android smartphone market, we expect that number to multiply greatly which will help us reach and support even more patients in the community.”
The new version of MyFactor includes basic improvements to the app’s visual design, user interface and report generator. More importantly, with the upcoming iOS app replacement, BioRx will have a common platform to release future enhancements that are currently in development, including the facilitation of two-way data exchange, secure cloud back-up, and integration with the BioRx pharmacy operating system. Planned for 2015, these features will be exclusive to BioRx customers.
The new Android platform is available for immediate download on Google Play. For more information, visit www.biorxhemophilia.com/myfactor.
About Hemophilia and Bleeding Disorders
Approximately 20,000 people in the U.S. have hemophilia, an inherited bleeding disorder characterized by episodes of prolonged bleeding. It affects males almost exclusively. Bleeding may occur spontaneously or as a result of trauma. Von Willebrand disease is a related bleeding disorder that affects males and females equally. Some estimates put the prevalence of von Willebrand disease as high as 1% to 2% of the U.S. population. Factor XIII deficiency is an extremely rare inherited blood disorder affecting 1 in 5 million live births. In affected individuals, the blood fails to clot appropriately, resulting in delayed wound healing. Each bleeding disorder is the result of a deficiency in or defective production of certain naturally occurring clotting factors in the bloodstream. Treatment is typically by intravenous infusion of commercially prepared hemophilia clotting factors.
Based in Cincinnati, Ohio, BioRx is one of the nation’s fastest growing providers of specialty pharmaceuticals and infusion services, delivering highly customized care for patients with certain rare and chronic diseases. In addition to serving patients with hemophilia and related bleeding disorders, BioRx offers pharmacy, nursing and education services to patients with hereditary angioedema, primary immune deficiencies, autoimmune disorders, alpha-1 antitrypsin deficiency, and nutrition and digestive disorders. The company’s clinical staff reaches patients and physicians in all 50 states. To learn more about BioRx and its products and services, visit www.biorx.com.